Eris Lifesciences [ERIS] vs Jubilant Pharmova [JUBLPHARMA] Detailed Stock Comparison
Eris Lifesciences
NSE
Loading...
Jubilant Pharmova
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Eris Lifesciences wins in 8 metrics, Jubilant Pharmova wins in 12 metrics, with 0 ties. Jubilant Pharmova appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Eris Lifesciences | Jubilant Pharmova | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 56.49 | 38.67 | Jubilant Pharmova |
| Price-to-Book Ratio | 7.62 | 2.84 | Jubilant Pharmova |
| Debt-to-Equity Ratio | 75.74 | 43.78 | Jubilant Pharmova |
| PEG Ratio | 1.35 | -0.49 | Jubilant Pharmova |
| EV/EBITDA | 22.85 | 15.76 | Jubilant Pharmova |
| Profit Margin (TTM) | 13.17% | 6.22% | Eris Lifesciences |
| Operating Margin (TTM) | 26.73% | 10.08% | Eris Lifesciences |
| EBITDA Margin (TTM) | 26.73% | 10.08% | Eris Lifesciences |
| Return on Equity | 10.75% | 13.45% | Jubilant Pharmova |
| Return on Assets (TTM) | 5.00% | 6.58% | Jubilant Pharmova |
| Free Cash Flow (TTM) | $9.10B | $-435.00M | Eris Lifesciences |
| Dividend Yield | 0.41% | 0.85% | Jubilant Pharmova |
| 1-Year Return | 15.28% | -4.20% | Eris Lifesciences |
| Price-to-Sales Ratio (TTM) | 7.42 | 2.40 | Jubilant Pharmova |
| Enterprise Value | $244.51B | $193.74B | Eris Lifesciences |
| EV/Revenue Ratio | 8.33 | 2.62 | Jubilant Pharmova |
| Gross Profit Margin (TTM) | 76.07% | 67.10% | Eris Lifesciences |
| Revenue per Share (TTM) | $216 | $467 | Jubilant Pharmova |
| Earnings per Share (Diluted) | $28.29 | $28.99 | Jubilant Pharmova |
| Beta (Stock Volatility) | -0.08 | 0.68 | Eris Lifesciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Eris Lifesciences vs Jubilant Pharmova Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Eris Lifesciences | 0.16% | 0.78% | -6.62% | -7.83% | 25.38% | 20.05% |
| Jubilant Pharmova | -1.10% | 1.74% | -0.71% | -8.51% | 24.32% | 1.69% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Eris Lifesciences | 15.28% | 121.28% | 224.18% | 165.70% | 165.70% | 165.70% |
| Jubilant Pharmova | -4.20% | 240.32% | 111.83% | 273.84% | 391.54% | 3,499.48% |
News Based Sentiment: Eris Lifesciences vs Jubilant Pharmova
Eris Lifesciences
News based Sentiment: MIXED
Eris Lifesciences reported positive financial results in Q1 FY26, with revenue and profit growth, but the initial market reaction was negative. The company's strategic move into the GLP-1 market adds a layer of potential, creating a mixed investment narrative that warrants close monitoring.
Jubilant Pharmova
News based Sentiment: POSITIVE
Jubilant Pharmova reported strong Q1 FY2025-26 results with significant growth in revenue, EBITDA, and PAT. The strategic acquisition of the API business from Jubilant Biosys signals a commitment to expansion and value creation, though a recent stock price dip and mixed analyst views add a layer of complexity.
Performance & Financial Health Analysis: Eris Lifesciences vs Jubilant Pharmova
| Metric | ERIS | JUBLPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹218.07B | ₹173.91B |
| Market Cap Category | Large cap | Mid cap |
| 10 Day Avg. Volume | 98,441 | 158,904 |
| 90 Day Avg. Volume | 128,261 | 167,454 |
| Last Close | ₹1,600.80 | ₹1,086.10 |
| 52 Week Range | ₹1,097.20 - ₹1,910.00 | ₹802.00 - ₹1,309.90 |
| % from 52W High | -16.19% | -17.09% |
| All-Time High | ₹1,910.00 (Jun 09, 2025) | ₹1,309.90 (Nov 04, 2024) |
| % from All-Time High | -16.19% | -17.09% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.10% |
| Quarterly Earnings Growth | 0.42% | -0.79% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.06% |
| Operating Margin (TTM) | 0.27% | 0.10% |
| Return on Equity (TTM) | 0.11% | 0.13% |
| Debt to Equity (MRQ) | 75.74 | 43.78 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹209.63 | ₹395.41 |
| Cash per Share (MRQ) | ₹15.09 | ₹68.67 |
| Operating Cash Flow (TTM) | ₹7.57B | ₹8.86B |
| Levered Free Cash Flow (TTM) | ₹3.52B | ₹8.39B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.41% | 0.85% |
| Last 12-Month Dividend | ₹7.35 | ₹10.00 |
Valuation & Enterprise Metrics Analysis: Eris Lifesciences vs Jubilant Pharmova
| Metric | ERIS | JUBLPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 56.49 | 38.67 |
| Forward P/E | 38.37 | 23.06 |
| PEG Ratio | 1.35 | -0.49 |
| Price to Sales (TTM) | 7.42 | 2.40 |
| Price to Book (MRQ) | 7.62 | 2.84 |
| Market Capitalization | ||
| Market Capitalization | ₹218.07B | ₹173.91B |
| Enterprise Value | ₹244.51B | ₹193.74B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.33 | 2.62 |
| Enterprise to EBITDA | 22.85 | 15.76 |
| Risk & Other Metrics | ||
| Beta | -0.08 | 0.68 |
| Book Value per Share (MRQ) | ₹209.63 | ₹395.41 |
Financial Statements Comparison: Eris Lifesciences vs Jubilant Pharmova
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ERIS | JUBLPHARMA |
|---|---|---|
| Revenue/Sales | ₹7.72B | ₹18.79B |
| Cost of Goods Sold | ₹1.85B | ₹6.18B |
| Gross Profit | ₹5.87B | ₹12.61B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹2.06B | ₹1.92B |
| EBITDA | ₹2.80B | ₹3.02B |
| Pre-Tax Income | ₹1.61B | ₹1.54B |
| Income Tax | ₹360.00M | ₹519.00M |
| Net Income (Profit) | ₹1.25B | ₹1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ERIS | JUBLPHARMA |
|---|---|---|
| Cash & Equivalents | ₹2.00B | ₹10.86B |
| Total Current Assets | ₹12.23B | ₹35.77B |
| Total Current Liabilities | ₹13.81B | ₹21.65B |
| Long-Term Debt | ₹17.82B | ₹23.89B |
| Total Shareholders Equity | ₹32.72B | ₹62.39B |
| Retained Earnings | ₹27.93B | ₹53.02B |
| Property, Plant & Equipment | ₹2.36B | ₹24.54B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ERIS | JUBLPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ERIS | JUBLPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 98,441 | 158,904 |
| Average Daily Volume (90 Day) | 128,261 | 167,454 |
| Shares Outstanding | 136.16M | 158.40M |
| Float Shares | 40.85M | 63.48M |
| % Held by Insiders | 0.69% | 0.58% |
| % Held by Institutions | 0.21% | 0.22% |
Dividend Analysis & Yield Comparison: Eris Lifesciences vs Jubilant Pharmova
| Metric | ERIS | JUBLPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹7.35 | ₹10.00 |
| Last 12-Month Dividend Yield | 0.41% | 0.85% |
| 3-Year Avg Annual Dividend | ₹4.90 | ₹6.67 |
| 3-Year Avg Dividend Yield | 0.82% | 0.89% |
| 3-Year Total Dividends | ₹14.70 | ₹20.00 |
| Ex-Dividend Date | Feb 13, 2025 | Jul 25, 2025 |